Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for securities fraud, related to safety issues with its Novum IQ Large Volume Pump, which has led to significant stock price decline and investor losses [1][5][6]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz are encouraging Baxter shareholders to inquire about a class action lawsuit filed on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1][2]. Safety Issues - On April 7, 2025, a Missouri news outlet reported serious safety concerns regarding Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Following this, Baxter issued warning letters about potential underinfusion risks, later revealing 79 reports of serious injuries and two patient deaths associated with the device [4]. Stock Price Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, resulting in a stock price drop of $6.24, or 22.4%, closing at $21.61 per share [5]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [6][7]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and misleading positive statements about its business prospects [7].

Core Insights - Baxter International Inc. (BAX) is set to release its third-quarter 2025 results on October 30, with expectations of modest growth despite recent mixed performance [1][3] Q3 Estimates - The consensus estimate for revenues is $2.87 billion, reflecting a 6.4% increase from the prior-year quarter [2] - Earnings per share (EPS) is projected at 60 cents, indicating a 25% year-over-year decline [2] Important Factors to Note - The company experienced a 4% growth in sales from continuing operations in the second quarter, supported by Drug Compounding, Advanced Surgery, and Care & Connectivity Solutions, but faced challenges in Infusion Therapies & Technologies and Injectables & Anesthesia [3] - Adjusted EPS for the second quarter was 59 cents, at the low end of guidance, while operating margin improved by 180 basis points to 15.1% [3] Management Expectations - For Q3, management anticipates revenue growth of 6-7% and operational growth of 3-4%, aided by foreign exchange tailwinds and approximately $80 million in MSA revenues from Vantive [4] - Adjusted EPS is expected to range between 58-62 cents, with margin stability anticipated despite volume pressures in IV solutions [4] Segmental Overview - **Medical Products & Therapies (MPT)**: Second-quarter sales rose 1% operationally to $1.3 billion, with Advanced Surgery growth offset by weakness in ITT [6] - **Healthcare Systems & Technologies (HST)**: Revenues increased 2% to $767 million, driven by 4% growth in CCS, with international strength [9] - **Pharmaceuticals**: Sales grew 1% to $612 million, with Drug Compounding growth offsetting declines in Injectables and anesthesia [10] - **Other Sales & Transitional Revenues**: Other sales totaled $13 million, with MSA revenues from Vantive contributing $98 million; projected MSA revenues for Q3 are nearly $80 million [11] Earnings Prediction Insights - The current model does not predict an earnings beat for Baxter, as the Earnings ESP is 0.00% [12] - Baxter holds a Zacks Rank of 3, indicating a hold position [13]

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for alleged securities fraud and unlawful business practices [2] - Baxter announced a voluntary and temporary pause in shipments and installations of its Novum LVP medical device, impacting its stock price significantly [2] Company Overview - Baxter International, Inc. is involved in the medical device sector, specifically focusing on intravenous fluid delivery systems [2] - The company has offered an alternative product, the Spectrum infusion pump, to customers affected by the pause in Novum LVP shipments [2] Financial Impact - Following the announcement of the shipment pause, Baxter's stock price dropped by $6.29 per share, representing a 22.4% decline, closing at $21.76 per share on July 31, 2025 [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [1][3]. Summary by Relevant Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - The firm has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [1]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks to patients [3]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, which led to serious injuries and deaths [3]. - Baxter's attempts to address these defects were deemed inadequate, and the company faced a heightened risk of halting sales of the Novum LVP [3]. Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover not affected by this decision [5]. Additional Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [5].

Accessibility StatementSkip Navigation NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contac ...

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the device but did not take adequate remedial measures, resulting in misleading statements about the product's safety and efficacy [5].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Baxter International, Spirit Aviation Holdings, and Molina Healthcare, with specific allegations of misleading statements and undisclosed risks during designated class periods [1]. Baxter International, Inc. (NYSE:BAX) - Class Period: February 23, 2022 to July 30, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Allegations include systemic defects in the Novum LVP leading to malfunctions that posed serious risks to patients, inadequate remedial measures by Baxter, and misleading statements regarding the safety and efficacy of the product [5]. Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ) - Class Period: May 28, 2025 to August 29, 2025 - Lead Plaintiff Deadline: December 1, 2025 - Allegations state that Spirit failed to disclose substantial risks of financial instability and potential bankruptcy, leading to a significant drop in stock price after the announcement of Chapter 11 filing [5]. Molina Healthcare, Inc. (NYSE:MOH) - Class Period: February 5, 2025 to July 23, 2025 - Lead Plaintiff Deadline: December 2, 2025 - Allegations include failure to disclose adverse facts regarding medical cost trends and misleading statements about the company's growth prospects, which could lead to a reduction in financial guidance for fiscal year 2025 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Baxter International, Inc. for misleading investors regarding the safety and operational issues of its Novum IQ Large Volume Pump, leading to significant financial losses for shareholders [1][5]. Summary by Sections Lawsuit Announcement - Glancy Prongay & Murray LLP has announced a class action lawsuit on behalf of Baxter investors who purchased shares between February 23, 2022, and July 30, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Safety Issues and Stock Impact - Reports surfaced on April 7, 2025, regarding serious safety issues with Baxter's Novum LVP, leading to its removal from a hospital system due to claims that the pumps were unsafe [2]. - Baxter issued warning letters about underinfusion risks on April 24, 2025, and later revealed 79 reports of serious injuries and two patient deaths related to the device, prompting a Class I recall from the FDA [3]. - Following the announcement of a pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's stock price dropped by $6.24, or 22.4%, closing at $21.61 per share [4]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [5][6]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and the risk of halting new sales of the Novum LVP due to safety concerns [5][6].

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)?Did you purchase your shares between February 23, 2022 and July 30, 2025, inclusive?Did you lose money in your investment in Baxter International Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline invo ...